Use	O
of	O
DNA	O
microarray	O
and	O
small	O
animal	O
positron	O
emission	O
tomography	O
in	O
preclinical	O
drug	O
evaluation	O
of	O
RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
VEGFR	O
-	O
2	O
inhibitor	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
has	O
become	O
a	O
useful	O
tool	O
for	O
assessing	O
early	O
biologic	O
response	O
to	O
cancer	B-Cancer
therapy	O
and	O
may	O
be	O
particularly	O
useful	O
in	O
the	O
development	O
of	O
new	O
cancer	B-Cancer
therapeutics	O
.	O

RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
inhibitor	O
,	O
was	O
evaluated	O
in	O
the	O
preclinical	O
setting	O
for	O
its	O
ability	O
to	O
inhibit	O
the	O
uptake	O
of	O
PET	O
tracers	O
in	O
the	O
A375M	B-Cell
(	I-Cell
B	I-Cell
-	I-Cell
Raf	I-Cell
(	I-Cell
V600E	I-Cell
)	I-Cell
)	I-Cell
human	I-Cell
melanoma	I-Cell
cell	I-Cell
line	I-Cell
.	O

RAF265	O
inhibited	O
2	O
-	O
deoxy	O
-	O
2	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoro	O
-	O
d	O
-	O
glucose	O
(	O
FDG	O
)	O
accumulation	O
in	O
cell	B-Cell
culture	I-Cell
at	O
28	O
hours	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

RAF265	O
also	O
inhibited	O
FDG	O
accumulation	O
in	O
tumor	B-Cancer
xenografts	I-Cancer
after	O
1	O
day	O
of	O
drug	O
treatment	O
.	O

This	O
decrease	O
persisted	O
for	O
the	O
remaining	O
2	O
weeks	O
of	O
treatment	O
.	O

DNA	O
microarray	O
analysis	O
of	O
treated	O
tumor	B-Cancer
xenografts	I-Cancer
revealed	O
significantly	O
decreased	O
expression	O
of	O
genes	O
regulating	O
glucose	O
and	O
thymidine	O
metabolism	O
and	O
revealed	O
changes	O
in	O
apoptotic	O
genes	O
,	O
suggesting	O
that	O
the	O
imaging	O
tracers	O
FDG	O
,	O
3	O
-	O
deoxy	O
-	O
3	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluorothymidine	O
,	O
and	O
annexin	O
V	O
could	O
serve	O
as	O
potential	O
imaging	O
biomarkers	O
for	O
RAF265	O
therapy	O
monitoring	O
.	O

We	O
concluded	O
that	O
RAF265	O
is	O
highly	O
efficacious	O
in	O
this	O
xenograft	B-Cancer
model	O
of	O
human	O
melanoma	B-Cancer
and	O
decreases	O
glucose	O
metabolism	O
as	O
measured	O
by	O
DNA	O
microarray	O
analysis	O
,	O
cell	B-Cell
culture	I-Cell
assays	O
,	O
and	O
small	O
animal	O
FDG	O
PET	O
scans	O
as	O
early	O
as	O
1	O
day	O
after	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
use	O
of	O
FDG	O
PET	O
in	O
clinical	O
trials	O
with	O
RAF265	O
to	O
assess	O
early	O
tumor	B-Cancer
response	O
.	O

DNA	O
microarray	O
analysis	O
and	O
small	O
animal	O
PET	O
studies	O
may	O
be	O
used	O
as	O
complementary	O
technologies	O
in	O
drug	O
development	O
.	O

DNA	O
microarray	O
analysis	O
allows	O
for	O
analysis	O
of	O
drug	O
effects	O
on	O
multiple	O
pathways	O
linked	O
to	O
cancer	B-Cancer
and	O
can	O
suggest	O
corresponding	O
imaging	O
tracers	O
for	O
further	O
analysis	O
as	O
biomarkers	O
of	O
tumor	B-Cancer
response	O
.	O

